A bill to provide clarification regarding the common or usual name for bison and compliance with section 403 of the Federal Food, Drug, and Cosmetic Act, and for other purposes.
Impact
The implementation of this bill may have significant implications for food producers and marketers. By establishing a clear distinction between 'buffalo' and the types of bison, it ensures that consumers are accurately informed about the products they are purchasing. This is particularly relevant in markets where bison meat is sold under the term 'buffalo', potentially affecting labeling and marketing strategies across the industry. The bill's provisions could lead to stricter compliance requirements for food manufacturers and retailers that market bison products.
Summary
SB258 aims to clarify the common or usual name for bison in relation to food labeling under the Federal Food, Drug, and Cosmetic Act. Specifically, the bill proposes to amend Section 403 of the Act by stating that food products containing any animal within the genus Bubalus labeled as 'buffalo' must clarify unless it specifically refers to the water buffalo. In a notable addition, the bill also allows the term 'buffalo' to be utilized as a common name for both the plains bison and the wood bison, thereby addressing potential ambiguities in food labeling practices.
Contention
While the bill is primarily technical in nature, there may be points of contention regarding the definitions and use of terms within the industry, especially concerning consumer perceptions and market dynamics. Stakeholders may debate the appropriateness of using 'buffalo' in labeling, considering possible confusion among consumers about the source of the meat. The distinction made by the bill could elicit responses from various interest groups, including those advocating for traditional food naming practices against those looking for clearer consumer information.
To nullify modifications made by the Food and Drug Administration on January 3, 2023, to the risk evaluation and mitigation strategy under section 505-1 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355-1) for mifepristone, and for other purposes.
To amend the Federal Food, Drug, and Cosmetic Act to encourage the development of vaccines to prevent, treat, or mitigate opioid, cocaine, methamphetamine, or alcohol use disorder, to establish an x-prize for the development of such a vaccine, and for other purposes.